Skip to main content
Equibles
KYNB logo

KYNB · Kyntra Bio, Inc.

Track KYNB — free

Use KYNB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.49 -0.04 (-0.47%)
Rebalance outlook locked
Market Cap
$34.01M
Shares
4.05M

Kyntra Bio, Inc. Earnings Call Transcripts

Quarterly earnings calls for Kyntra Bio, Inc. (KYNB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼89.9% $15.73M −$91.65M '22 Q3 22-11-07 ▲107.7% $34.37M −$66.17M '22 Q4 23-02-27 ▼40.6% $36.16M −$76.70M '23 Q1 23-05-08 ▲48.7% $44.32M −$87.68M '23 Q2 23-08-07 ▲155.1% $40.13M −$63.62M '23 Q3 23-11-06 ▼314.8% $ −$56.23M '23 Q4 24-02-26 ▼29.9% $25.36M −$32.93M '24 Q1 24-05-06 ▼97.7% $998,000 −$15.54M '24 Q2 24-08-06 ▼99.7% $123,000 −$17.08M '24 Q3 24-11-12 · $3.14M $17.98M '24 Q4 25-02-20 ▼89.2% $2.74M $4.64M '25 Q1 25-05-12 ▲35.1% $1.35M −$7.60M '25 Q2 25-08-11 ▲774.8% $1.08M $200.64M '25 Q3 25-11-10 ▼59.3% $1.28M −$14.22M '25 Q4 26-03-16 ▲36.5% $3.74M −$15.20M '26 Q1 26-05-11 LATEST ▼209.3% $ $11.97M '26 Q2 26-08-13
Earnings call
FY26 · Q2
2026-08-13
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call
Revenue
$
▼ 209.3% YoY
Diluted EPS
$2.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Positive tone FG-3246 ADC program in mCRPC Roxadustat in lower-risk MDS Phase II monotherapy dose optimization trial
Revenue
$3.74M
▲ 36.5% YoY
Diluted EPS
$-3.76
▼ 427% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Positive tone FG-3246 / FG-3180 in mCRPC IST combination data (FG-3246 + enzalutamide) Companion diagnostic / PET imaging strategy
Revenue
$1.28M*
▼ 59.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Kyntra Bio, Inc. (KYNB) Q3 2025 Earnings Call Transcript
Positive tone Roxadustat in lower-risk MDS CD46 vs PSMA target differentiation and competition Sale of FibroGen China to AstraZeneca
Revenue
$1.08M
▲ 774.8% YoY
Diluted EPS
$49.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Kyntra Bio, Inc. (KYNB) Q2 2025 Earnings Call Transcript
Positive tone FG-3246 and FG-3180 in mCRPC Roxadustat for lower-risk MDS Sale of FibroGen China to AstraZeneca
Revenue
$1.35M
▲ 35.1% YoY
Diluted EPS
$-1.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Kyntra Bio, Inc. (KYNB) Q1 2025 Earnings Call Transcript
Confident tone FG-3246 ADC Program in mCRPC FG-3180 PET Imaging Agent Roxadustat in MDS (Lower-Risk Myelodysplastic Syndromes)
Revenue
$2.74M
▼ 89.2% YoY
Diluted EPS
$1.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Kyntra Bio, Inc. (KYNB) Q4 2024 Earnings Call
Revenue
$3.14M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Kyntra Bio, Inc. (KYNB) Q3 2024 Earnings Call
Revenue
$123,000
▼ 99.7% YoY
Diluted EPS
$-4.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Kyntra Bio, Inc. (KYNB) Q2 2024 Earnings Call
Revenue
$998,000
▼ 97.7% YoY
Diluted EPS
$-3.89
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings Call
Revenue
$25.36M
▼ 29.9% YoY
Diluted EPS
$-8.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Kyntra Bio, Inc. (KYNB) Q4 2023 Earnings Call
Revenue
$*
▼ 314.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Kyntra Bio, Inc. (KYNB) Q3 2023 Earnings Call
Revenue
$40.13M
▲ 155.1% YoY
Diluted EPS
$-16.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Kyntra Bio, Inc. (KYNB) Q2 2023 Earnings Call
Revenue
$44.32M
▲ 48.7% YoY
Diluted EPS
$-22.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Kyntra Bio, Inc. (KYNB) Q1 2023 Earnings Call
Revenue
$36.16M
▼ 40.6% YoY
Diluted EPS
$-20.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Kyntra Bio, Inc. (KYNB) Q4 2022 Earnings Call
Revenue
$34.37M*
▲ 107.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Kyntra Bio, Inc. (KYNB) Q3 2022 Earnings Call
Revenue
$15.73M
▼ 89.9% YoY
Diluted EPS
$-24.50
▼ 281.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Kyntra Bio, Inc. (KYNB) Q2 2022 Earnings Call
Revenue
$29.81M
▲ 22.3% YoY
Diluted EPS
$-19.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Kyntra Bio, Inc. (KYNB) Q1 2022 Earnings Call
Revenue
$60.83M
▲ 58.3% YoY
Diluted EPS
$-17.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Kyntra Bio, Inc. (KYNB) Q4 2021 Earnings Call
Revenue
$16.54M*
▼ 74.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Kyntra Bio, Inc. (KYNB) Q3 2021 Earnings Call
Revenue
$155.97M
▲ 254.2% YoY
Diluted EPS
$13.50
▲ 54.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Kyntra Bio, Inc. (KYNB) Q2 2021 Earnings Call
Revenue
$24.36M
▼ 43.2% YoY
Diluted EPS
$-36.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Kyntra Bio, Inc. (KYNB) Q1 2021 Earnings Call
Revenue
$38.43M
▲ 57.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Kyntra Bio, Inc. (KYNB) Q4 2020 Earnings Call
Revenue
$65.00M*
▲ 715.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Kyntra Bio, Inc. (KYNB) Q3 2020 Earnings Call
Revenue
$44.03M
▲ 32.7% YoY
Diluted EPS
$8.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Kyntra Bio, Inc. (KYNB) Q2 2020 Earnings Call
Revenue
$42.89M
▼ 77.6% YoY
Diluted EPS
$-23.75
▼ 175.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Kyntra Bio, Inc. (KYNB) Q1 2020 Earnings Call
Revenue
$24.40M
▲ 2.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Kyntra Bio, Inc. (KYNB) Q4 2019 Earnings Call
Revenue
$7.97M*
▼ 92.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 921299 CUSIP 31572Q881 13F (30d) 27 filings 26 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)